TY - JOUR
T1 - Modelling Parkinson's Disease in C. elegans
T2 - Strengths and Limitations
AU - Ma, Liang
AU - Li, Xi
AU - Liu, Chengyu
AU - Yan, Wanyao
AU - Ma, Jinlu
AU - Petersen, Robert B.
AU - Peng, Anlin
AU - Huang, Kun
N1 - Funding Information:
This work was supported by the Natural Science Foundation of China (NSFC No. 82273838, 81901302, 31971066 and 31671195), the Wuhan Municipal Health Research Foundation (WZ20Q02), Wuhan Municipal Health Youth Talent Training Program, the Key project of the Natural Science Foundation of Hubei Province (2021CFA004), and Integrated Innovative Team for Major Human Diseases Program of Tongji Medical College, HUST.
Publisher Copyright:
© 2022 Bentham Science Publishers.
PY - 2022/10
Y1 - 2022/10
N2 - Parkinson's disease (PD) is a common neurodegenerative disease that affects the motor system and progressively worsens with age. Current treatment options for PD mainly target symptoms, due to our limited understanding of the etiology and pathophysiology of PD. A variety of preclinical models have been developed to study different aspects of the disease. The models have been used to elucidate the pathogenesis and for test-ing new treatments. These models include cell models, non-mammalian models, rodent models, and non-human primate models. Over the past few decades, Caenorhabditis elegans (C. elegans) has been widely adopted as a model system due to its small size, transparent body, short generation time and life cycle, fully sequenced genome, the tractability of genetic manipulation and suitability for large scale screening for disease modifiers. Here, we review studies using C. elegans as a model for PD and highlight the strengths and limitations of the C. elegans model. Various C. elegans PD models, including neurotoxin-induced models and genetic models, are described in detail. Moreover, methodologies employed to investigate neurodegeneration and phenotypic deficits in C. elegans are summarized.
AB - Parkinson's disease (PD) is a common neurodegenerative disease that affects the motor system and progressively worsens with age. Current treatment options for PD mainly target symptoms, due to our limited understanding of the etiology and pathophysiology of PD. A variety of preclinical models have been developed to study different aspects of the disease. The models have been used to elucidate the pathogenesis and for test-ing new treatments. These models include cell models, non-mammalian models, rodent models, and non-human primate models. Over the past few decades, Caenorhabditis elegans (C. elegans) has been widely adopted as a model system due to its small size, transparent body, short generation time and life cycle, fully sequenced genome, the tractability of genetic manipulation and suitability for large scale screening for disease modifiers. Here, we review studies using C. elegans as a model for PD and highlight the strengths and limitations of the C. elegans model. Various C. elegans PD models, including neurotoxin-induced models and genetic models, are described in detail. Moreover, methodologies employed to investigate neurodegeneration and phenotypic deficits in C. elegans are summarized.
KW - C. elegans
KW - Parkinson’s disease
KW - animal model
KW - genetic models
KW - high-throughput screening
KW - neurotoxin-induced models
KW - pathological hallmarks
UR - http://www.scopus.com/inward/record.url?scp=85142304006&partnerID=8YFLogxK
U2 - 10.2174/1381612828666220915103502
DO - 10.2174/1381612828666220915103502
M3 - Review article
C2 - 36111767
AN - SCOPUS:85142304006
VL - 28
SP - 3033
EP - 3048
JO - Current Pharmaceutical Design
JF - Current Pharmaceutical Design
SN - 1381-6128
IS - 37
ER -